Skip to main content

Table 2 Effect of long-term (10 weeks) empagliflozin treatment on body weight, tibia length, visceral fat weight, subcutaneous fat weight, liver weight, and left ventricular weight of SHRcp

From: Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome

 

Control (n = 12)

SGLT2 (n = 12)

Body weight (g)

733.3 ± 5.3

664.0 ± 9.2*

Tibia length (mm)

39.1 ± 0.1

39.0 ± 0.1

Epididymal fat weight (g)

6.4 ± 0.2

7.0 ± 0.3

Mesenteric fat weight (g)

12.3 ± 0.2

11.8 ± 0.2

Perirenal fat weight (g)

56.2 ± 1.0

53.8 ± 1.3

Subcutaneous fat weight (g)

69.0 ± 1.5

52.7 ± 2.2*

Liver weight (g)

29.5 ± 0.74

28.6 ± 0.35

Left ventricular weight (mg)

1465 ± 44

1363 ± 16#

  1. Control SHRcp fed control diet; SGLT2 SHRcp fed control diet containing empagliflozin. Values are mean ± SEM. Statistical analysis was performed by unpaired Student’s t test
  2. # P < 0.05, * P < 0.01 versus control
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840